お知らせ • Feb 18
Silo Wellness Inc. Announces Resignation of Gerard Lee from as A Director of the Board Silo Wellness Inc. accepted the resignation of Gerard Lee from his position as a director of the board, effective immediately. The board of directors includes Greg Biniowsky (independent director), Vancouver lawyer; Simon Bababeygy, M.D. (independent director), California physician; Michael Hartman, California pharmaceutical chemist; and Mike Arnold, Oregon lawyer. お知らせ • Oct 18
Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd. Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Silo Wellness Inc. (CNSX:SILO) entered into a definitive share exchange agreement to acquire Dyscovry Science Ltd. on September 27, 2022. Pursuant to the terms of the Share Exchange Agreement, Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange for 12,762,325 (for a total of 49% of the issued shares post closing of the transaction) common shares in the capital of Silo (the "Payment Shares"). The Payment Shares issued for shares of Dyscovry shall be subject to restrictions on resale for a period of 36 months from closing of the Acquisition and shall be released on a schedule consistent with the release schedule for an "emerging issuer" prescribed by section 4.3 of National Policy 46-201- Escrow for Initial Public Offerings. Silo has also agreed to pay approximately CAD 120,000 of Dyscovry founder's debt in twelve equal monthly installments, and in any event, the total debt shall be paid no later than twelve months from the Closing Date. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange of 49% of the issued shares. Following closing, Dyscovry shall have the right to immediately nominate one director to the board of directors of Silo. Closing of the Transaction is subject to customary closing conditions and applicable regulatory approvals, including the approval of the CSE and the shareholders of Dyscovry if required.
Silo Wellness Inc. (CNSX:SILO) completed the acquisition of Dyscovry Science Ltd. on October 17, 2022. Upon closing of the transaction, CFO Winfield Ding has resigned from the board of directors and Dyscovry founder Gerard Lee of Toronto has been appointed director. Winfield Ding will continue as Chief Financial Officer. お知らせ • Jun 10
Silo Wellness Inc. Announces Change of Chief Executive Officer Silo Wellness Inc. announced that founder and chairman of the board of directors Mike Arnold is assuming the role of the company's interim chief executive officer to continue to lead the company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney. As the company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12 million for his startups. Mike received his Bachelor of Arts from Truman State University (Kirksville, Missouri) and Juris Doctor from the University of Oregon School of Law. He is an avid outdoorsman and rafting guide. お知らせ • Jun 01
Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. Silo Wellness Inc. (CNSX:SILO) executed a nonbinding letter of intent to acquire Dyscovry Science Ltd. on May 31, 2022. Subject to the completion of the due diligence process and the completion of the definitive agreement, the transaction contemplates Silo Wellness Inc. acquiring 100% of Dyscovry's shares in exchange for 49% of the issued outstanding securities of the Company. お知らせ • Apr 15
Silo Wellness Inc. announced that it expects to receive CAD 5.95 million in funding from Alpha Blue Ocean Investment Group Silo Wellness Inc. announced that it has entered into an subscription agreement for a private placement of convertible debentures for gross proceeds of up to CAD 5,950,000 on April 14, 2022. The transaction will include participation from new investor Global Tech Opportunities 14, a fund managed by Alpha Blue Ocean Investment Group. The subscription agreement provides a commitment to fund the corporation up to CAD 5,950,000 by subscribing for CAD 7,300,000 aggregate principal amount of convertible debentures, inclusive of the commitment fee, in twenty tranches, each in the aggregate principal amount of CAD 350,000 each tranche convertible upon notice at the lower of the closing price of the common shares on the CSE at the time of delivery of the relevant conversion notice to the corporation and CAD 0.05; the convertible debentures shall be subscribed for at a subscription price of eighty-five percent of the par value of the convertible debentures. 41,650,000 warrants exercisable at CAD 0.05 shall be attached to the first tranche. In connection with the subscription agreement, the company has agreed to pay the subscriber a commitment fee of CAD 300,000 where CAD 150,000 shall be added to the principal amount of the debentures issued in connection with each of the first two tranches. お知らせ • Feb 04
Silo Wellness Inc. announced that it expects to receive $0.494988 million in funding from Orthogonal Thinker, Inc., Investment Arm Silo Wellness Inc. announced that it has entered into an subscription agreement to issue 12,555,180 units at a price of $0.039425 per unit for gross proceeds of up to $494,988 on February 3, 2022. The transaction will include participation from new investor Orthogonal Thinker, Inc., Investment Arm. Each unit will consist of one common share and one common share purchase warrant. Each warrant will be exercisable at CAD 0.05 per share for two years following the closing date of the offering. The offering is subject to customary closing conditions, applicable regulatory approvals, including receipt of certain voting support agreements from certain shareholders of the company. David Nikzad and Jason Hobson from Orthogonal Thinker, Inc., Investment Arm will join company's board of director. お知らせ • Jun 25
Silo Wellness Inc. Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley Family Silo Wellness Inc. announced the launch of Marley One, the first global functional and psychedelic mushroom consumer brand, in collaboration with the family of Bob Marley. The initial product offering will include a range of functional mushroom tinctures with unique blends highlighting the brand’s connection to Jamaica, including species such as cordyceps, lion's mane, chaga, reishi and turkey tail that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. The Company intends to launch a psychedelic mushroom product line under the Marley name later this year, to be followed by additional functional mushroom products including gummies, capsules and cosmetics. In March, Silo Wellness announced a multi-year licensing agreement with the family of global reggae icon Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. At launch, the Marley One product line includes: One Mind: A coffee-flavored blend of lion’s mane and L-theanine designed to improve focus and cognitive function. One Flow: A peppermint-flavored blend of cordyceps and ginseng designed to enhance physical endurance and mental function. One Harmony: A mango-flavored blend of chaga and ginger designed to stimulate gut health and improve digestion. One Body: A berry-flavored blend of turkey tail and astragalus designed to support immune health. One Rest: A vanilla-flavored blend of reishi and GABA designed to help reduce tension and stress and improve quality of sleep.